We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other stocks that Jim Cramer discusses.
During the lightning round, a caller asked about Biohaven Ltd., and Cramer commented:
“Alright, Biohaven had an analyst day the other day, and it was, you know, people didn’t get excited about it. Now, in full disclosure, I do have a personal deal with Biohaven, and I don’t talk about it much because it’s not been disclosed, but I am surprised this stock is all the way down here. Vlad Coric is really good. I think that this is a buy, but you could say, hey Cramer, you’re biased, you got a deal with them. But I’m just telling you that’s how I feel, or else I wouldn’t have a deal with them.”
A pharmacist in a white coat with a range of drugs on shelves behind her.
Biohaven works on creating and advancing treatments in the fields of immunology, neuroscience, and cancer. On April 22, Cramer was asked about the company, and he said:
“Alright, first, in pure disclosure, Biohaven, I’m working with them. They’ve bought a drug from me, that I made for me, and a terrific guy, Larry Newman, Dr. Newman, to help solve tinnitus so I always want to tell people that. The stock at $21, I think, therefore, is too cheap. But you might say, oh, that’s just Jim talking because he sold his drug to them. But no, I think the stock is very cheap, and Vlad Coric, who’s the CEO, I think, is really terrific. So I would be a buyer of the stock.”
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
This article is originally published at Insider Monkey.
